Sumitomo Pharma Co., Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SMDPY research report →
Price Chart
About the company
Sumitomo Pharma Co. , Ltd. operates as a global entity focused on the development, manufacturing, and distribution of a diverse range of products.
- CEO
- Toru Kimura
- IPO
- 2022
- Employees
- 4,980
- HQ
- Osaka, OS, JP
Get TickerSpark's AI analysis on SMDPY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.63B
- P/E
- 5.66
- PEG
- 0.01
- P/S
- 1.50
- P/B
- 1.69
- EV/EBITDA
- 6.02
- Div Yield
- 0.00%
- Gross Margin
- 54.99%
- Op Margin
- 10.05%
- Net Margin
- 23.73%
- ROE
- 35.89%
- ROIC
- 7.64%
Latest fiscal year · YoY change
- Revenue
- $480.63B+20.5%
- Gross Profit
- $272.39B+11.0%
- Op Income
- $53.38B
- Net Income
- $113.31B+379.4%
- EPS
- $286.01+380.8%
- OCF Growth
- +360.8%
- FCF Growth
- +1950.5%
- 52W High
- $24.48
- 52W Low
- $7.84
- 50D MA
- $9.59
- 200D MA
- $11.05
- Beta
- 0.46
- RSI (14)
- 58
- Avg Volume
- 736
No earnings-call transcripts are available for SMDPY yet.
- Free Float
- 53.2%
- Shares Outstanding
- 448.59M
- Float Shares
- 238.43M
Our SMDPY coverage
Recent articles, reports, and earnings notes.
No research on SMDPY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SMDPY report →Sumitomo Pharma America Announces First Patient Receives Treatment in Phase 1/2a Study for its Investigational Therapy DSP-3077 for Retinitis Pigmentosa
businesswire.com · Aug 12
Sumitomo Pharma America Achieves Key Patient Enrollment Milestone for Pivotal Phase 2 Study of Enzomenib in the Treatment of Relapsed/Refractory Acute Leukemia
businesswire.com · Jun 10
Sumitomo Pharma Co., Ltd. (DNPUF) Discusses R&D Progress, Oncology Pipeline, and Advances in Regenerative Medicine and Vaccines Transcript
seekingalpha.com · Feb 20
Sumitomo Pharma shares plunge 12% despite greenlight for Parkinson's treatment
cnbc.com · Feb 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.